2NZ9 image
Deposition Date 2006-11-22
Release Date 2006-12-26
Last Version Date 2024-11-13
Entry Detail
PDB ID:
2NZ9
Title:
Crystal structure of botulinum neurotoxin type A complexed with monoclonal antibody AR2
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.79 Å
R-Value Free:
0.27
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Botulinum neurotoxin type A
Chain IDs:A, B
Chain Length:1295
Number of Molecules:2
Biological Source:Clostridium botulinum
Polymer Type:polypeptide(L)
Molecule:AR2 monoclonal antibody
Chain IDs:C, E
Chain Length:218
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:AR2 monoclonal antibody
Chain IDs:D, F
Chain Length:224
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin.
Nat.Biotechnol. 25 107 116 (2007)
PMID: 17173035 DOI: 10.1038/nbt1269

Abstact

Broadening antibody specificity without compromising affinity should facilitate detection and neutralization of toxin and viral subtypes. We used yeast display and a co-selection strategy to increase cross-reactivity of a single chain (sc) Fv antibody to botulinum neurotoxin type A (BoNT/A). Starting with a scFv that binds the BoNT/A1 subtype with high affinity (136 pM) and the BoNT/A2 subtype with low affinity (109 nM), we increased its affinity for BoNT/A2 1,250-fold, to 87 pM, while maintaining high-affinity binding to BoNT/A1 (115 pM). To find the molecular basis for improved cross-reactivity, we determined the X-ray co-crystal structures of wild-type and cross-reactive antibodies complexed to BoNT/A1 at resolutions up to 2.6 A, and measured the thermodynamic contribution of BoNT/A1 and A2 amino acids to wild-type and cross-reactive antibody binding. The results show how an antibody can be engineered to bind two different antigens despite structural differences in the antigen-antibody interface and may provide a general strategy for tuning antibody specificity and cross-reactivity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures